Welcome to our dedicated page for OSMT news (Ticker: OSMT), a resource for investors and traders seeking the latest updates and insights on OSMT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OSMT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OSMT's position in the market.
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced the results of its Annual General Meeting held on June 17, 2021. Shareholders approved a resolution waiving obligations under Rule 37 of the Irish Takeover Rules, allowing for potential future repurchases of up to 6,271,913 ordinary shares. This may increase the shareholding percentage of specific parties, including Avista Healthcare Partners and Altchem Limited, without requiring them to make a general offer. Current and potential shareholdings were outlined, reflecting significant ownership concentration among these groups.
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced its participation in the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 p.m. Eastern Time. Presenters include CEO Brian Markison, COO James “JD” Schaub, and CFO Andrew Einhorn. The presentation will be accessible via a live webcast, which will also be archived for 30 days on the company's website. Osmotica focuses on developing specialty products for underserved patient populations and operates in both the U.S. and Hungary.
Osmotica Pharmaceuticals reported Q1 2021 revenues of $23.9 million, down from $48.6 million in Q1 2020, primarily due to a decline in product sales. The net loss widened to $9.6 million from $3.1 million a year earlier. Notably, Upneeq prescription sales increased by 74% over Q4 2020, and April saw a further 17% growth compared to March. The company aims to submit a revised study protocol for arbaclofen to the FDA soon and is considering divesting non-core assets.
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference. The presentation is scheduled for May 19, 2021, at 4:50 p.m. Eastern Time. Interested participants can join the live webcast and access the archived presentation for 30 days via the company’s website. Osmotica focuses on developing specialty products for underserved patient markets and has operations in the U.S., Argentina, and Hungary.
Osmotica Pharmaceuticals (Nasdaq: OSMT) is set to announce its first quarter 2021 financial results on May 13, 2021, after U.S. market close. CEO Brian Markison, COO JD Schaub, and CFO Andrew Einhorn will conduct a conference call at 4:30 p.m. ET. Investors can access the call via a toll-free number or through the company's website for a live and replay webcast. Osmotica specializes in biopharmaceuticals aimed at underserved patient populations, with operations in the U.S., Argentina, and Hungary.
Osmotica Pharmaceuticals announced its fourth quarter and full year 2020 financial results, reporting total revenues of $34.5 million for Q4 and $177.9 million for the year. The company received FDA approval for Upneeq, the first treatment for acquired ptosis in adults, and established a global brand through a licensing agreement with Santen Pharmaceuticals. Despite a decline in net product sales largely due to increased competition, Osmotica reduced debt by $50 million and ended the year with $114.1 million in cash. However, the net loss for Q4 reached $54.9 million.
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced its fourth quarter and full year 2020 financial results will be released on March 30, 2021, after market close. The company’s executives, including CEO Brian Markison, will host a conference call at 4:30 p.m. ET the same day to discuss the results. Osmotica focuses on developing specialty products for underserved patient populations, with operations in the U.S., Argentina, and Hungary, and subsidiaries including RVL Pharmaceuticals, which supports the product UPNEEQ.
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the Barclays Global Healthcare Conference on March 9, 2021, at 9:45 a.m. Eastern Time. The presentation will be available via webcast at this link. Osmotica focuses on developing specialty biopharmaceuticals, with operations in the U.S., Argentina, and Hungary, and offers a diverse portfolio, including products from its ophthalmic subsidiary, RVL Pharmaceuticals.
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 9:20 a.m. Eastern Time. The presentation will be accessible via webcast at this link. Osmotica is a biopharmaceutical company focusing on specialty products for underserved markets, with operations in the U.S., Argentina, and Hungary.
